Abstract

Persister cells are a small subpopulation within fungal biofilms that are highly resistant to high concentrations of antifungals and therefore most likely contribute to the resistance and recalcitrance of biofilm infections. Moreover, this subpopulation is defined as a nongrowing, phenotypic variant of wild-type cells that can survive high doses of antifungals. There are high degrees of heterogeneity and plasticity associated with biofilm formation, resulting in a strong variation in the amount of persister cells. The fraction of these cells in fungal biofilms also appear to be dependent on the type of substrate. The cells can be observed immediately after their adhesion to that substrate, which makes up the initial step of biofilm formation. Thus far, persister cells have primarily been studied in Candida spp. These fungi are the fourth most common cause of nosocomial systemic infections in the United States, with C. albicans being the most prevalent species. Remarkably, persisters exhibit characteristics of a dormant state similar to what is observed in cells deprived of glucose. This dormant state, together with attachment to a substrate, appears to provide the cells with characteristics that help them overcome the challenges with fungicidal drugs such as amphotericin B (AmB). AmB is known to induce apoptosis, and persister cells are able to cope with the increase in reactive oxygen species (ROS) by activating stress response pathways and the accumulation of high amounts of glycogen and trehalose—two known stress-protecting molecules. In this review, we discuss the molecular pathways that are involved in persister cell formation in fungal species and highlight that the eradication of persister cells could lead to a strong reduction of treatment failure in a clinical setting.

Highlights

  • The global AIDS crisis, the use of implants, and the higher survival rates of immunocompromised patients have resulted in an increase in invasive fungal infections [1,2]

  • October 18, 2018 treatment failure, but here we will only focus on how pathogens are able to survive fungicidal drug exposure

  • We refer to polyenes, such as amphothericin B (AmB), echinocandins, such as caspofungin, and miconazole, a fungicidal azole antifungal drug

Read more

Summary

Introduction

The global AIDS crisis, the use of implants, and the higher survival rates of immunocompromised patients have resulted in an increase in invasive fungal infections [1,2]. Biofilms are associated with increased resistance against antifungal agents and host immune factors They can result in treatment failure [5]. Persister cells are a specialized case of tolerance [11] They are nongrowing, phenotypic variants of wild-type cells and constitute only a small part of the biofilm population that is able to survive high doses of antifungal treatment (Fig 1). Persister cells constitute a subset of the biofilm that is refractory to killing, even at very high antifungal drug concentrations Because of this, they can only be detected when fungicidal drugs are used, but it is not known whether Candida persister cells are present in the absence of antifungals. SC5314 3153A YEM30 SC5314 BF-1 ATCC90030 T1570 ATCC13803 T1427 GZY803 BWP17 S 1278b YS-

Culture conditions before challenge
Do persister cells contribute to in vivo persistence?
Findings
Outlook and perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call